西酞普兰,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
1317	*4	The CYP2C194 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C194 allele in combination with a no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.
1316	*3	The CYP2C193 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C193 allele in combination with a no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.
1315	*2	The CYP2C192 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C192 allele in combination with a normal or no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.
1314	*1	The CYP2C191 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C191 allele in combination with a normal function allele who are treated with citalopram may have decreased, but not absent, risk for treatment related side effects or intolerance as compared to patients with two no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

等位基因

注释文本

The CYP2C19*4 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*4 allele in combination with a no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

1316

The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

1315

The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a normal or no function allele who are treated with citalopram may have increased risk for treatment related side effects or intolerance as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

1314

The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with a normal function allele who are treated with citalopram may have decreased, but not absent, risk for treatment related side effects or intolerance as compared to patients with two no function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence treatment related side effects.

id	证据的ID	总结
1144	1183619955	CYP2C19 2 + 3 +17 are not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 1.
1143	1450415299	CYP2C19 1/2 is not associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with citalopram, escitalopram or sertraline in people with Cardiovascular Diseases and Depression as compared to CYP2C19 1/1.
1142	1183619350	CYP2C19 2 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 1/*1.
1141	1183619342	CYP2C19 4 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 1/*1.
1140	1451715793	Genotype AG is associated with increased likelihood of adverse events due to citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.
1139	1449717838	CYP2C19 poor metabolizer phenotype is not associated with risk of adverse events due to citalopram or escitalopram in people with as compared to CYP2C19 normal metabolizer phenotype.
1138	1184748582	CYP2C19 poor metabolizers is associated with increased risk of electrocardiogram qt prolonged when treated with citalopram as compared to CYP2C19 normal metabolizers.
1137	1183701647	CYP2C19 poor metabolizers is not associated with increased risk of intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.
1136	PA166104977	Annotation of DPWG Guideline for citalopram and CYP2C19
1135	PA166127638	Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19

证据的ID

总结

1144

1183619955

CYP2C19 *2 + *3 +*17 are not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1.

1143

1450415299

CYP2C19 *1/*2 is not associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with citalopram, escitalopram or sertraline in people with Cardiovascular Diseases and Depression as compared to CYP2C19 *1/*1.

1142

1183619350

CYP2C19 *2 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.

1141

1183619342

CYP2C19 *4 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.

1140

1451715793

Genotype AG is associated with increased likelihood of adverse events due to citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.

1139

1449717838

CYP2C19 poor metabolizer phenotype is not associated with risk of adverse events due to citalopram or escitalopram in people with as compared to CYP2C19 normal metabolizer phenotype.

1138

1184748582

CYP2C19 poor metabolizers is associated with increased risk of electrocardiogram qt prolonged when treated with citalopram as compared to CYP2C19 normal metabolizers.

1137

1183701647

CYP2C19 poor metabolizers is not associated with increased risk of intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.

1136

PA166104977

Annotation of DPWG Guideline for citalopram and CYP2C19

1135

PA166127638

Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19

id	类型	评论
1457	Update	Added PMID 33608663 to evidence. Minor edits to phenotype descriptions.
1456	Update	Added DPWG guideline.
1455	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1454	Create	Created

类型

1457

Update

Added PMID 33608663 to evidence. Minor edits to phenotype descriptions.

1456

Update

Added DPWG guideline.

1455

Update

CA score added as part of scoring system release. LOE assigned following curator review.

1454

Create